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Abstract 
Background: Low-dose computed tomography (CT) screening can detect early stage lung cancer in high-risk populations. However, no 
data on repeated annual screening over more than 5 years are available, and the impact of screening on lung cancer mortality is 
controversial. 
Methods: We analysed outcomes in high-risk asymptomatic volunteers (smokers and former smokers, >50 years) enrolled in a pilot 
study over 1 year from June 2000, who received annual low-dose CT for 7 years. Cumulative lung cancer incidence and survival were 
represented by Kaplan−Meier curves. Standardized incidence and mortality ratios were used to estimate risks relative to the general 
Italian and US population. 
Results: Compliance was 86% at the end of the seventh year in 1035 recruited volunteers (71% men, mean age 58 years). Lung cancer 
was diagnosed in 54 (5.3%); radical surgery was possible in 48/54 (87%); 39/54 (72%) had stage I disease. Five-year survival was 63% 
overall, 89% for stage I cases. During 6308 person-years of observation, 47 participants had died versus 75 expected in the Italian 
general population standardised for age and sex. Fourteen lung cancer deaths were registered versus 27 expected in a standardised US 
smoker population.  
Conclusions:  Seventy percent of screening-diagnosed patients had stage I disease, and the survival of screen-detected cancer 
patients was high. Lung cancer mortality was favourable compared to age- and sex-matched population of US smokers, suggesting that 
mortality can be lowered by screening, although larger trials with longer follow-up are necessary to confirm these findings. 
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Introduction 
Lung cancer, already a leading cause of cancer death 
worldwide, is characterized by increasing incidence among 
women in western countries and among both sexes in 
developing countries [1, 2]. The disease is usually rapidly fatal 
from time of diagnosis not only because it is biologically 
aggressive, but also because it is typically diagnosed at an 
advanced stage [3]. As the chances of cure depend strongly on 
the stage of cancer at diagnosis [4] and because smokers are at 
greatly increased risk of lung cancer [5], anticipation of 
diagnosis by screening the high-risk population constitutes a 
potentially important tool for reducing lung cancer mortality. The 
most promising screening modality is low-dose spiral CT of the 
chest [6-8], since, with an examination lasting for a few 
seconds, the technique can identify lung nodules of just a few 
millimetre in diameter, without contrast, with low radiation 
exposure and limited costs. However, no data on the results of 
repeated CT screening over more than 5 years are available. 
Furthermore, data on the impact of CT screening on mortality 
are few and controversial. The encouraging results of I-ELCAP 
− in which patients with screening-detected lung cancer had 
estimated lung cancer-specific survival of 80% at 10 years [9] − 
contrast with the absence of evidence for reduction in lung 
cancer deaths when screening outcomes in pilot studies were 
compared with those predicted by models [10]. Nevertheless, a 
model predicting outcome using data from participants in the 
Mayo [8] CT-screening study [11] indicated a 28% reduction in 
the lung cancer mortality at 6 years due to screening, although 
the reduction in all-cause mortality was only 2% at 15 years due 
to increased mortality from non-lung cancer causes associated 
with smoking. We report on long-term outcomes in a screened 
population that has undergone seven or more annual screening 
scans for lung cancer, focusing on the survival and stage 
distribution at diagnosis of those diagnosed with lung cancer, 
and the disease-specific mortality and mortality for competing 
risks in the entire screened population. 
 
Methods 
We enrolled 1035 high-risk volunteers in a pilot-screening study 
over 1 year, starting in June 2000. By August 2007, those 
enrolled had received the baseline low-dose CT scan plus 
seven annual screening scans. The eighth scanning round has 
been completed but data are not yet available. Recruitment 
criteria were: age >50 years, and a smoking history of more
than 20 pack-years, with former smokers giving up smoking not 
more than 10 years previously. Subjects were recruited from all 
over the country but most were from Milan area in Italy. A 
single-detector scanner was used up to 2004, since then 8-or 
16-detector scanners have been used.  
The CT-screening parameters and workup algorithm have been 
published elsewhere [12]. Briefly volunteers with a nodule >5 
mm were initially recalled for high-resolution CT and those with 
lesions >7 mm received PET (or PET/CT). After multi-detector 
CT screening was introduced, high-resolution CT was no longer 
performed and suspicious nodules >5 mm were assessed by 
CT/PET or repeated low-dose CT at 3-month intervals. The 
study was approved by our Institute’s Ethics Committee. All 
participants were informed about the methods and aim of the 
study and signed a written informed consent form.  
 
Statistical methods 
Evaluation of lung cancer incidence and mortality in 
comparison with background 
We calculated the number of person-years at risk from the date 
of first CT until the date of last contact or death. The expected 
numbers of lung cancer cases and of deaths for any cause or 
specific causes were calculated by multiplying the number of 
person-years accumulated in each stratum of age and sex by 
the corresponding age- and sex-specific lung cancer incidence 
[13] and mortality rates reported for the general population in 
Italy [14]. Standardized incidence (SIR) and mortality ratios 
(SMR) − ratios of observed to expected cases/deaths − were 
used to estimate relative risks. The expected number of deaths 
due to lung cancer was also estimated from published age- and 
sex-specific mortality rates observed in the smokers 
participating in the US Cancer Prevention Study II [15, 16].  
Cumulative lung cancer incidence and survival 
Cumulative lung cancer incidence and survival were 
represented according to Kaplan−Meier, and the log-rank test 
was used to assess the significance of differences between 
groups. Subjects were right-censored if they were alive at the 
end of the study period or alive at some time but later lost to 
follow up. The analyses were performed with SAS version 8.2 
(Cary, NC). All p values refer to two-sided tests. 
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Table 1: Numbers of lung cancers diagnosed, and number (with %) diagnosed at stage 1 over the period 2000 to 2008 in a high-risk population 
recruited to the CT-screening trial. 
Results 
The enrolled population of 1035 consisted of 739 (71%) men 
and 296 (29%) women, of mean age 58 years (range 50−76), 
890 (86%) of whom were smokers and 145 (14%) former 
smokers. At the end of March 2008, 852 had presented for the 
seventh screening scan. Study compliance was 852/988 
(86.2%) (1035 recruited minus 47 deaths = 988). One hundred 
and eight smokers at baseline (13%) stopped smoking after 
enrolment and 14 (2%) former smokers started smoking again 
during follow-up. Fifty four (42 men, 12 women) were diagnosed 
with lung cancer. Mean age at diagnosis was 62 years (range 
50−76). One interval cancer occurred (diagnosed between 
repeated scans due to occurrence of symptoms).  
Forty-five patients received radical surgery (44 lobectomies; 1 
segmentectomy). Eight patients (four diagnosed by 
mediastinoscopy, two by fine needle aspiration and two by 
thoracoscopic biopsy) received non-surgical treatment. One 
patient was treated elsewhere and the type of treatment is 
unknown.  
According to the new TNM classification system (seventh 
edition) [17], disease stage at diagnosis is shown in Figure 1. 
Thirty-eight patients (70%) had stage I NSCLC (35 stage IA and
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Table 2: Observed lung cancer incidence and mortality during 6308 person-years of observation in a high-risk population recruited to CT-
screening trial in comparison with expected incidence and mortality in the Italian general population (low risk) 
 
ICD9: Ninth version of the International Classification of Diseases (WHO); SIR: standardized incidence rate; SMR: standardized mortality rates; CI: 
confidence intervals. 
*Liver cirrhosis (n = 2), car accident (n = 2), foot gangrene (n = 1), renal insufficiency (n = 1), unknown (n = 2). 
3 stage I B). The stage distribution of the patients at diagnosis is 
shown in Table 1 which indicates that on average the high 
proportion of stage I diagnoses was maintained over 7 years. 
Morphologies were adenocarcinoma in 33 (61%), squamous 
cell carcinoma in 7 (13%), small cell carcinoma in 7 (13%), 
carcinoid in 2 (4%), and not otherwise specified non-small cell 
lung cancer in 5 (9%). Overall 5-year survival was 63%; survival 
for stage I A and B disease was 89% (Figure 2).  
Ten patients (15.6%) were operated on for benign disease with 
no postoperative morbidity or mortality. Mean size of lung 
cancers at preoperative CT scan were 19 mm for baseline 
cancers and 14 mm for cancers detected at subsequent 
screening rounds.  
In the absence of data on lung cancer incidence and mortality 
rates in a comparable population of non-screened smokers, we 
decided to compare the number of cases from lung cancer in 
our series with that expected applying age- and sex-specific 
cancer incidence reported in the general Italian population. This 
will represent only an indirect quantification of the risk since the 
prevalence of smoking in Italy was about 31% in men and 22% 
in women during the study period with approximately 20% of 
men and 10% of women reporting smoking more than 15 
cigarettes per day [18]. During 6308 person-years of 
observation, 54 volunteers were diagnosed with lung cancer 
compared to 14 expected using the cancer rates observed in 
the Italian general population (SIR 4.0; 95% confidence interval 
[CI] 2.74−5.63).    
Fourteen lung cancer deaths were observed in our series 
compared to 10 expected in the Italian general population 
however this includes only about 20% smokers versus 100% in 
our study (SMR 1.43; 96% CI 0.642.74) (Table 2). Therefore, in  
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Table 3: Observed lung cancer deaths during 6308 person-years of observation on a high-risk population recruited to CT-screening trial in 
comparison to expected lung cancer-specific death rate in a population of US smokers [18] 
the screened series we had a standardised disease-specific 
mortality risk of 1.4 versus a standardised incident risk of 4.0. 
This represents an indirect sign of the beneficial effect of 
screening. 
Note that the Italian general population is at lower risk of lung 
cancer incidence due to lower smoking prevalence (only 20% 
compared to 100% in the study population). 
While cancer mortality rates in smokers were not available in 
Italy, we attempted to assess the benefit of screening using 
mortality and survival rates extrapolated from US smokers in the 
Cancer Prevention Study II [15].  After standardising for age and 
sex, the observed lung cancer deaths in our screened Italian 
population were significantly lower than expected in the 
unscreened US smoker population (14 observed versus 27 
expected with an SMR 0.51 95% CI 0.23−0.98) (Table 3). 
 
Discussion 
Studies of chest X-ray and sputum cytology screening for lung 
cancer, conducted in the 1970s, showed no mortality benefit 
[19-21]. Mass screening for lung cancer was therefore 
abandoned and is not currently recommended. Interest in lung 
cancer screening has revived recently however, because of 
reports indicating that low-dose CT can detect smaller and 
earlier stage lung cancers than conventional X-ray [6, 7]. Large-
scale randomised controlled trials [22, 23] are currently in 
progress to determine the efficacy of low-dose CT-screening but 
definitive results will not be available for several years.  
The main controversies surrounding lung cancer screening are 
over-diagnosis (identification of nonfatal cancers) [24] and the 
lack of demonstration of mortality reduction [10]. In this study, 
most (72%) cancers were stage I, confirming the potential 
benefit of screening in terms of chance of cure even after the 
first couple of screening rounds. Not more than 16% of 
symptom-detected cancers in the US are stage I and II 
according to SEER statistics [3]. Over the seven years of 
repeated screening in our study, the rate of diagnosis of early 
stage disease was maintained (Table 1). 
This experience is in contrast to that reported in brief pilot 
studies [10, 12, 24] and emphasizes the importance of 
continuing annual screening for more than 5 years. Our 
experience in fact undermines the hypothesis that over-
diagnosis is a problem with lung cancer screening. If over-
diagnosis were a major phenomenon, the proportion of stage I 
cancers would be expected to decrease after the first couple of 
annual screening rounds, due to depletion of supposed non-
fatal cases. Other evidence also indicates that non-fatal cancers 
form only a small proportion of lung cancers: almost all patients 
diagnosed with stage I lung cancer by chest X-ray screening 
and not treated, died of the disease [25-27]. Furthermore 
pathological and molecular analyses indicate that the 
morphology and genetic characteristics of screening-detected 
cancers are closely similar to those of symptoms-detected 
cancers [28-30].  
In this study, the high overall (63%) and stage I survival (89%) 
at five years are consistent with the highly encouraging results 
of the I-ELCAP study [9] but at odds with the analysis of Bach et 
al. [10] which was applied to three pilot studies on lung cancer 
screening including the one we performed. This modelling 
analysis found that CT screening increased the rate of detection 
of lung cancers but did not much reduce the risk of advanced 
lung cancer or of lung cancer deaths. As we pointed out in [31], 
the analysis had limitations including too short a follow-up time 
and the exclusion the data of the first year of screening when 
comparing deaths. In fact, one of the authors of [10] 
emphasized that the model used could have missed a 
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difference in mortality rate of up to 30%. (Does CT screening 
reduce Lung Cancer Mortality? James R. Jett, MD Speaker, 
Controversies Around Cancer Screening, Special Session, 
2008; personal communication ASCO Annual Meeting.)  
In the absence of data on lung cancer incidence and mortality 
rates in a comparable population of non-screened smokers, we 
compared the number of cases and deaths from lung cancer in 
our series with that expected applying age- and sex-specific 
cancer incidence and mortality rates reported in the general 
Italian population. This will represent only an indirect 
quantification of the risk since the prevalence of smoking in Italy 
was about 31% in men and 22% in women during the study 
period with approximately 20% of men and 10% of women 
reporting smoking more than 15 cigarettes per day [18]. During 
6308 person-years of observation, 54 volunteers were 
diagnosed with lung cancer compared to 14 expected using the 
cancer rates observed in the Italian general population (SIR 4.0; 
95% confidence interval [CI] 2.74−5.63).  
It is worth noting that lung cancer incidence in our screened 
population was four-fold higher than that of the general Italian 
population due to the higher exposure to smoking while the risk 
of death was only 1.4-fold higher. This difference is probably 
due to a beneficial effect of screening.  
While cancer mortality rates in smokers were not available in 
Italy, we attempted to assess the benefit of screening using 
mortality and survival rates extrapolated from US smokers in the 
Cancer Prevention Study II [15].   
The comparison of mortality rate observed in our screened 
volunteers with [13] that expected in a population of US citizens 
of similar age, sex distribution and smoking habits confirmed a 
benefit of about 31−61% reduction in lung cancer deaths (SMR 
0.51 95% CI 0.23−0.98) (Table 3). Although this direct 
comparison can be misleading since other competing risk 
factors are likely to differ between the two populations, it 
provides a further indication that lung cancer mortality may be
reduced by screening. Our results are also in line with two other 
recent publications [11, 32]. In McMahon et al. [11], a micro-
simulation model estimated a reduction in lung cancer-specific 
mortality by 28% at 6 years in subjects who received five annual 
CT scans compared to observation. The meta-analysis of Chien 
et al. [32] conducted on six studies indicated that CT can 
advance the diagnosis of asymptomatic lung cancers by 2 years 
compared to observation and reduce lung cancer mortality by 
23% at 5 years, again compared to observation.  
Two limitations of this pilot study is the absence of a true control 
group of subjects and the lack of an evaluation of psychological 
impact of screening. 
Points of strengths are the single centre recruitment with high 
homogeneity in diagnosis and treatment, the high compliance 
and long duration of the study.  
To conclude, our long-term study has shown that a high 
proportion (70%) of the cancers diagnosed over seven annual 
screening rounds were at stage IA and IB, and that overall 
actuarial 5-year survival of patients with screening-detected 
cancers was high (63%). Lung cancer mortality was favourable 
when compared both to the general Italian population and to an 
age- and sex-matched population of US smokers, indicating that 
low-dose CT screening of high-risk subjects may reduce lung 
cancer mortality.  
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